602 studies found for:    Open Studies | ovarian cancer
Show Display Options
Rank Status Study
1 Recruiting Interactive Educational Website for Women With Ovarian Cancer & Caregivers
Conditions: Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Recurrent Ovarian Cancer;   Fallopian Tube Cancer
Interventions: Behavioral: Usual Care Educational Website;   Behavioral: Prototype System
2 Recruiting Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART) With Carboplatin and Docetaxel in Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Carcinoma;   Recurrent Ovarian Cancer;   Recurrent Ovarian Carcinoma
Interventions: Radiation: Low Dose Fractionated Whole Abdominal Radiation Therapy;   Drug: Carboplatin;   Drug: Docetaxel
3 Recruiting Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of Ovary;   Cancer of the Ovary;   Ovary Neoplasms;   Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
4 Unknown  Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Conditions: Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review;   Other: study of socioeconomic and demographic variables;   Procedure: disease screening;   Procedure: evaluation of cancer risk factors;   Procedure: genitourinary surgical procedure;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
5 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
6 Recruiting Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Conditions: Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Uterine Cancer
Interventions: Drug: Olaparib;   Drug: Carboplatin;   Drug: Paclitaxel
7 Recruiting Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Conditions: Recurrent Ovarian Cancer;   Platinum Sensitive Ovarian Cancer
Intervention: Drug: Carboplatin
8 Recruiting Blood Collection From People With Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of the Ovary;   Ovarian Neoplasms
Intervention:
9 Recruiting Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Drug: 18F-EF5 PET/CT scan;   Procedure: Optional biopsy
10 Not yet recruiting PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conditions: Ovarian Neoplasms;   Neoplasms, Ovarian;   Ovarian Cancer
Interventions: Drug: Pazopanib;   Drug: Fosbretabulin
11 Not yet recruiting Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Recurrent Ovarian Cancer;   Recurrent Endometrial Cancer
Interventions: Drug: BKM120;   Drug: Nabpaclitaxel
12 Recruiting A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Conditions: Ovarian Cancer;   Malignant Female Reproductive System Neoplasm;   Cancer;   Ovarian Tumor;   Ovarian Epithelial Cancer Recurrent
Interventions: Drug: DOXIL/CAELYX;   Drug: ATI-0918
13 Not yet recruiting H.O.P.E: Helping Ovarian Cancer Patients Cope
Conditions: Platinum-resistant Ovarian Cancer;   Recurrent Ovarian Cancer;   Palliative Care
Interventions: Other: Structured Palliative Care;   Other: Usual Care
14 Recruiting Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Conditions: Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma;   Ovarian Carcinoma;   Fallopian Tube Carcinoma
Interventions: Procedure: Cytoreductive Surgery (CRS);   Drug: Systemic Chemotherapy;   Other: Questionnaire;   Procedure: Hyperthermic intraperitoneal chemotherapy;   Drug: Carboplatin;   Drug: Paclitaxel
15 Recruiting Salvage Ovarian FANG Vaccine + Bevacizumab
Conditions: Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Biological: FANG™ Vaccine;   Drug: Bevacizumab
16 Recruiting Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer at Low Genetic Risk
Conditions: Ovarian Cancer;   Breast Cancer
Intervention: Drug: LY2606368
17 Recruiting Salvage Ovarian FANG Vaccine + Carboplatinum
Conditions: Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Biological: Vaccine: FANG™ Vaccine;   Drug: Carboplatinum;   Drug: Carboplatinum and Taxol;   Biological: FANG
18 Recruiting AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Conditions: Breast Cancer;   Ovarian Cancer
Intervention: Drug: AZ2281 + Carboplatin
19 Recruiting Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses
Conditions: Ovarian Carcinoma;   Ovarian Cancer;   Ovarian Mass;   Ovarian Cyst
Interventions: Other: Ultrasound by general gynaecologist;   Other: Ultrasound by an expert ultrasonographist;   Other: DW-MRI;   Other: Give blood sample
20 Recruiting Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention: Procedure: Tumor Debulking Surgery (surgery in recurrent ovarian disease)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years